ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apixaban

Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.

Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.

Drug pageApixaban: every studyMany companies study it; this page follows only the 37 they lead. All 179 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 6, 201337 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only260 open or runningphase 4since Jun 6, 2013Nov 22, 2004none ahead
Pfizer60 open or runningphase 4since Feb 5, 2014Nov 5, 2008none ahead
Artivionits history only10 open or runningphase 3since Oct 9, 2019Oct 9, 2019none ahead
Dexa Medica Groupits history only10 open or runningphase 1since Feb 5, 2025Feb 5, 2025none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Sep 4, 2023Sep 4, 2023none ahead
Scotmann Pharmaceuticalsits history only10 open or runningphase 2since Oct 21, 2021Oct 21, 2021none ahead
TAHO Pharmaceuticalsits history only10 open or runningearly phase 1since Jul 24, 2023Jul 24, 2023none ahead

Also a collaborator on its studies: Link Medical Research AB, Parexel and PT Equilab International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2008First study: phase 2 study in Atrial FibrillationFirst studyNCT00787150 · 222 enrolled · Japan
  2. Feb 26, 2009Phase 2 study in Acute Coronary SyndromeNCT00852397 · 151 enrolled · Japan
  3. Jun 3, 2009Phase 1 study in ThrombosisNCT00914641 · 16 enrolled · United States
  4. Sep 20, 2011Phase 1 study in HealthyNCT01437839 · 22 enrolled · Singapore
  5. Jan 29, 2013Phase 3 study in Venous ThrombosisNCT01780987 · 80 enrolled · Japan
  6. Feb 5, 2014Phase 4 study in Atrial FibrillationNCT02100228 · 1,500 enrolled · United States, Belgium, Canada and more

TargetBeta

F10 →read by rule
“Coagulation factor X inhibitor”ChEMBL 37, by rule

Other programs on F10

ProgramCompanyFurthest phaseStudies
RivaroxabanruleBayerphase 477
emicizumabruleHoffmann-La Rochephase 413
Factor Xrulekedrion-s-p-aphase 31

Studies

All 6 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02100228Atrial Fibrillation · United States, Belgium, Canada and more4CompletedFeb 8, 20171,500
NCT01780987Venous Thrombosis · Japan3CompletedSep 201480
NCT01437839Healthy · Singapore1CompletedOct 201122
NCT00914641Thrombosis · United States1CompletedAug 200916
NCT00852397Acute Coronary Syndrome · Japan2TerminatedDec 2010151
NCT00787150Atrial Fibrillation · Japan2CompletedSep 2009222

How it is read

Names in the registry

  • “Apixaban”, 38 entries
  • “Apixaban 5 MG”, 2 entries
  • “apixaban”, 2 entries
  • “Apixaban 5 mg Oral Tablet”, 1 entry
  • “Apixaban 5MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.